CRESCENT BIOPHARMA, INC. (CBIO) Balance Sheet
As of 2026-06-30 (10-Q), CRESCENT BIOPHARMA, INC. (CBIO) reported total assets of $182.8M, total liabilities of $19.5M and shareholders' equity of $163.3M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $171.6M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CBIOCRESCENT BIOPHARMA, INC.Follow CBIO — free
—
Price chart with a free account
- Market cap
- 476.2M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
| Line | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 55.2 | 46.8 | 40.0 | 123.9 | 209.9 | 158.2 | 137.0 | 90.3 | 47.9 | 41.8 | 34.8 | 213.2 | 171.6 | |
| Receivables | — | — | — | — | — | — | — | — | — | — | 0.0 | 18.0 | 0.0 | |
| Current assets | 56.1 | 47.2 | 40.5 | 127.2 | 212.3 | 162.5 | 138.3 | 90.8 | 50.7 | 43.8 | 34.8 | 236.7 | 179.0 | |
| Total assets | 57.3 | 48.5 | 42.4 | 128.6 | 214.8 | 168.0 | 142.8 | 94.3 | 51.8 | 45.3 | 35.6 | 240.3 | 182.8 | |
| Current liabilities | 6.5 | 7.7 | 6.3 | 8.2 | 8.8 | 11.0 | 12.4 | 11.8 | 8.9 | 6.8 | 9.6 | 36.1 | 18.5 | |
| Long-term debt | — | — | — | — | — | — | — | — | — | — | 37.5 | 0.0 | — | |
| Total liabilities | 6.5 | 8.0 | 7.1 | 8.9 | 9.4 | 13.8 | 14.6 | 12.7 | 8.9 | 6.9 | 47.1 | 37.3 | 19.5 | |
| Shareholders' equity | 50.8 | 40.5 | 35.3 | 119.7 | 205.5 | 154.2 | 128.2 | 81.6 | 42.9 | 38.4 | -15.5 | 203.0 | 163.3 |
USD millions · SEC XBRL
CRESCENT BIOPHARMA, INC. — questions
- How much cash does CRESCENT BIOPHARMA, INC. have?
- $171.6M in cash and cash equivalents as of 2026-06-30.
- What are CRESCENT BIOPHARMA, INC.'s total assets?
- $182.8M as of 2026-06-30.
- What is CRESCENT BIOPHARMA, INC.'s shareholders' equity?
- $163.3M as of 2026-06-30.
Every figure on this page comes from CRESCENT BIOPHARMA, INC.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.